DE60032590D1 - METHOD FOR TREATING SCHIZOPHRENIA - Google Patents

METHOD FOR TREATING SCHIZOPHRENIA

Info

Publication number
DE60032590D1
DE60032590D1 DE60032590T DE60032590T DE60032590D1 DE 60032590 D1 DE60032590 D1 DE 60032590D1 DE 60032590 T DE60032590 T DE 60032590T DE 60032590 T DE60032590 T DE 60032590T DE 60032590 D1 DE60032590 D1 DE 60032590D1
Authority
DE
Germany
Prior art keywords
cells
therapeutic cells
schizophrenia
eps
negative symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60032590T
Other languages
German (de)
Other versions
DE60032590T2 (en
Inventor
C Allen
Michael Cornfeldt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Titan Pharmaceuticals Inc
Original Assignee
Titan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Titan Pharmaceuticals Inc filed Critical Titan Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60032590D1 publication Critical patent/DE60032590D1/en
Publication of DE60032590T2 publication Critical patent/DE60032590T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Telephonic Communication Services (AREA)
  • Discharging, Photosensitive Material Shape In Electrophotography (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention provides methods for the treatment of abnormal psychiatric states, particularly the negative symptoms of schizophrenia and extrapyramidal side effects (EPS) of antipsychotic drugs. The inventive methods relate to the administration of therapeutic cells (which produce dopamine or dopamine precursors) adhered to support matrices to subjects suffering from the negative symptoms of schizophrenia and/or EPS. The therapeutic cells may be coadministered with cells which protect the therapeutic cells from immune rejection and/or cells which produce neurotrophic factors which improve the viability of the therapeutic cells.
DE60032590T 1999-04-09 2000-03-20 METHOD FOR TREATING SCHIZOPHRENIA Expired - Fee Related DE60032590T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US289576 1994-08-12
US09/289,576 US7115256B1 (en) 1999-04-09 1999-04-09 Methods of treating schizophrenia
PCT/US2000/007514 WO2000061156A2 (en) 1999-04-09 2000-03-20 Methods of treating schizophrenia

Publications (2)

Publication Number Publication Date
DE60032590D1 true DE60032590D1 (en) 2007-02-08
DE60032590T2 DE60032590T2 (en) 2007-10-11

Family

ID=23112130

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60032590T Expired - Fee Related DE60032590T2 (en) 1999-04-09 2000-03-20 METHOD FOR TREATING SCHIZOPHRENIA

Country Status (18)

Country Link
US (2) US7115256B1 (en)
EP (1) EP1165100B1 (en)
JP (1) JP2003532621A (en)
AT (1) ATE349218T1 (en)
AU (1) AU778494B2 (en)
CA (1) CA2369439A1 (en)
CY (1) CY1106371T1 (en)
DE (1) DE60032590T2 (en)
DK (1) DK1165100T3 (en)
ES (1) ES2275501T3 (en)
HK (1) HK1040054B (en)
IL (3) IL145815A0 (en)
MX (1) MXPA01010131A (en)
NO (1) NO20014890L (en)
NZ (1) NZ514652A (en)
PT (1) PT1165100E (en)
WO (1) WO2000061156A2 (en)
ZA (1) ZA200108251B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115256B1 (en) * 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
DE10138275A1 (en) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Connections to eliminate anhedonia
WO2004108144A1 (en) * 2003-06-06 2004-12-16 Kringle Pharma Inc. Cell-containing preparations
US20070065422A1 (en) * 2005-09-20 2007-03-22 Cameron Don F Induction of immune tolerance by sertoli cells
US7940978B2 (en) * 2007-06-05 2011-05-10 General Electric Company Automatic characterization of cellular motion
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
US20100060713A1 (en) * 2008-09-10 2010-03-11 Eastman Kodak Company System and Method for Enhancing Noverbal Aspects of Communication
KR20120007139A (en) * 2010-07-14 2012-01-20 주식회사 파미니티 Composition for preventing and treating brain diseases comprising carbon nanotube as an active ingredient
WO2014128882A1 (en) * 2013-02-21 2014-08-28 医療法人 和楽会 Therapeutic agent for anxiety depression
US11690876B2 (en) 2017-05-10 2023-07-04 University Of Rochester Methods of treating neuropsychiatric disorders
JP2021524841A (en) 2018-05-24 2021-09-16 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー Implantable device for sustained release of macromolecular drug compounds
MX2020012459A (en) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE464816B (en) 1985-10-15 1991-06-17 Nilsson Kjell MACROPOROUS PARTICLES, PROCEDURES FOR ITS PREPARATION AND ITS APPLICATION
US5650148A (en) 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5447948A (en) 1992-05-07 1995-09-05 Yale University Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
DK0755258T3 (en) 1994-04-13 2002-05-13 Res Corp Technologies Inc Method of treating disease using Sertoli cells and allo-graft or xeno-graft
WO1998056393A1 (en) 1997-06-13 1998-12-17 University Technology Corporation Transplantation of immortalized dopamine cells to improve neurological deficits
EP1044024A1 (en) 1998-01-02 2000-10-18 Titan Pharmaceuticals, Inc. Use of pigmented retinal epithelial cells for creation of an immune privilege site
US7115256B1 (en) * 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia

Also Published As

Publication number Publication date
NZ514652A (en) 2004-06-25
DE60032590T2 (en) 2007-10-11
ZA200108251B (en) 2002-12-24
CA2369439A1 (en) 2000-10-19
US7115256B1 (en) 2006-10-03
EP1165100B1 (en) 2006-12-27
ATE349218T1 (en) 2007-01-15
IL145815A (en) 2008-12-29
AU3907100A (en) 2000-11-14
MXPA01010131A (en) 2002-08-20
HK1040054A1 (en) 2002-05-24
PT1165100E (en) 2007-02-28
JP2003532621A (en) 2003-11-05
IL145815A0 (en) 2002-07-25
DK1165100T3 (en) 2007-05-07
WO2000061156A2 (en) 2000-10-19
NO20014890D0 (en) 2001-10-08
CY1106371T1 (en) 2011-10-12
AU778494B2 (en) 2004-12-09
US20060292128A1 (en) 2006-12-28
IL177538A0 (en) 2006-12-10
EP1165100A2 (en) 2002-01-02
ES2275501T3 (en) 2007-06-16
NO20014890L (en) 2001-12-05
HK1040054B (en) 2007-08-10
WO2000061156A3 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
IL177538A0 (en) Compositions for treating schizophrenia
DK1885382T3 (en) Methods for using adipose tissue-derived cells in the treatment of cardiovascular conditions
UA109878C2 (en) Isoquinolinone derivatives, pharmaceutical composition based on them (variants), and method of treating diseases (variants)
DK1539166T3 (en) Pharmaceutical compositions containing dextromethorphan and quinidine for the treatment of neurological disorders
DK0721449T3 (en) Inhibitors of beta-amyloid protein production
ATE362766T1 (en) APOLIPOPROTEIN A-I AGONISTS AND THEIR USE IN THE TREATMENT OF DISLIPIDEMIC DISEASES
TW200510306A (en) Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
MA33806B1 (en) INHIBITORS OF HEPATITIS C VIRUS
DK1599575T3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
BR112021019070A2 (en) tyk2 pseudokinase ligands
BR112021022380A2 (en) jak inhibitors
DK0556332T3 (en) Substituted tetrahydropyridines and hydroxypiperidines as agents for the treatment of the central nervous system
ATE385807T1 (en) PHARMACEUTICAL COMPOUND AND METHODS FOR TREATING HUMAN CARCINOMA USING ARGININE WITHDRAWAL
MA27607A1 (en) CYTO-MODULATING PEPTIDES TO TREAT INTERSTITIAL CYSTITIS
ATE328887T1 (en) CONDENSED HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
BR112022002390A2 (en) jak inhibitors
BR112022005608A2 (en) JAK INHIBITORS
DE60009315D1 (en) USE OF CYAMEMAZINE FOR THE TREATMENT OF DEWANNING SYMPTOMS OF THE BENZODIAZEPINE TREATMENT
DE60010934D1 (en) Medicines suitable for the treatment of proliferative diseases
DE602004016547D1 (en) 1,4-DIHYDROPYRIDINE COMPOUNDS, PHARMACEUTICAL COMPOUNDS, AND METHOD FOR THE TREATMENT OF CARDIAC DISORDER
DK1778834T3 (en) Methods for the use of regenerative cells in the treatment of renal diseases and disorders
DE60215219D1 (en) USE OF DARIFENACINE FOR THE TREATMENT OF THE HARNDRANGS
UA92908C2 (en) Compounds derived from 5-thioxylose and therapeutic use thereof
DE602004015321D1 (en) 1,4-DIHYDROPYRIDINE COMPOUNDS, PHARMACEUTICAL COMPOUNDS, AND METHOD FOR THE TREATMENT OF CARDIAC DISORDER
ATE535246T1 (en) COMPOSITION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee